Genetic Analysis Full Year 2023 Earnings: kr0.62 loss per share (vs kr1.13 loss in FY 2022)

Genetic Analysis (NGM:GEAN) Full Year 2023 Results

Key Financial Results

• Revenue: kr23.2m (up 12% from FY 2022).
• Net loss: kr23.8m (loss narrowed by 16% from FY 2022).
• kr0.62 loss per share (improved from kr1.13 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the USA segment contributing a total revenue of kr7.32m (32% of total revenue). The largest operating expense was General & Administrative costs, amounting to kr20.7m (49% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of kr105.8k. Explore how GEAN's revenue and expenses shape its earnings.

Genetic Analysis shares are down 58% from a week ago.

Risk Analysis

Before you take the next step you should know about the 6 warning signs for Genetic Analysis (5 make us uncomfortable!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.